早期诊断阿尔茨海默病的PET分子探针

蔡汉成; 尹端沚; 张岚; 李谷才; 郑明强; 汪勇先

早期诊断阿尔茨海默病的PET分子探针

蔡汉成 , 尹端沚 , 张岚 , 李谷才 , 郑明强 , 汪勇先

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 4: (202-205)

引用本文:

Citation:

早期诊断阿尔茨海默病的PET分子探针

201800 上海, 中国科学院上海应用物理研究所放射性药物研究中心

通讯作者: 蔡汉成, chcbati@yahoo.com.cn ;

基金项目:
中国科学院知识创新工程重大项目(KJCXI-SW-08):上海市自然科学基金项目(02ZB14061)
中图分类号: R817.4

PET molecular probes for early detection of Alzheimer's disease

Research Center of Radiopharmaceuticals Shanghai Institute of Applied Physics, the Chinese Academy of Sciences, Shanghai 201800, China

Corresponding author: CAI Han-cheng, chcbati@yahoo.com.cn ;

CLC number: R817.4

摘要: 阿尔茨海默病(AD)是一种退行性神经功能障碍性疾病,其典型病理学特征是β-淀粉样蛋白斑块、神经纤维缠结和基底前脑乙酰胆碱能损害。PET分子探针,特别是靶向β-淀粉样蛋白斑块、乙酰胆碱酯酶或受体显像的分子探针是最可靠的AD早期检测手段之一。
- 阿尔茨海默病 /
- 体层摄影术,发射型计算机 /
- 分子探针 /
- 淀粉样β蛋白 /
- 受体,胆碱能
Abstract: Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. The characteristic pathological lesions are deposits of β-amyloid plaques and neurofibrillary tangles after postmortem examination, and degeneration of cholinergic neurons of the basal forebrain. The positron emission tomography (PET) molecular probes targeting at β-amyloid plaques or acetylchergic is one of the most reliable tools for AD early detection.
- lzheimer's disease /
- Tomography, emission-computed /
- Molecular probe /
- Aamyloid β-protein /
- Recepter, cholinergic
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Verdile G,Fuller S,Atwood CS,et al.The role of beta amyloid in Alzheimer's disease:still a cause of everything or the only one who got caught.Pharmacol Res,2004,50(4):397-409.
[2]	Court JA,Piggott MA,Lloyd S,et al.Nicotine binding in human striatum:elevation in schizophrenia and reductions in dementia with Lewy bodies,Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.Neurosci,2000,98(1):79-87.
[3]	Nora DV,Ding YS,Joanna SF,et al.Imaging brain cholinergic activity with positron emission tomography:its role in the evaluation of cholinergic treatments in Alzheimer's dementia.Biol Psychiatry,2001,49(3):211-220.
[4]	De Leon MJ,Convit A,Wolf OT,et al.Prediction of cognitive decline in normal elderly subjects with 2-[¹⁸F] fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).Proc Natl Acad Sci USA,2001,98(19):10966-10971.
[5]	Hard J,Selkoe DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics.Science,2002,297(5590):353-356.
[6]	Zhang Y,Pavlova OA,Chefer SI,et al.5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy) pyridine with low picomolar affinity for alpha 4 beta 2 nicotinic acetylcholine receptor and wide range of lipophilicity:potential probes for imaging with positron emission tomography.J Med Chem.2004,47(10):2453-2465.
[7]	Mathis CA,Bacskai BJ,Kajdasz ST,et al.A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.Bioorg Med Chem Lett,2002,12(3):295-298.
[8]	Klunk WE,Engler H,Nordberg A,et al.Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B.Ann Neurol,2004,55(3):306-319.
[9]	Kung HF,Lee CW,Zhuang ZP,et al.Novel stilbenes as probes for amyloid plaques.J Am Chem Soc,2001,123(50):12740-12741.
[10]	Suemoto T,Okamura N,Shiomostu T,et al.In vivo labeling of amyloid with BF-108.Neurosci Res,2004,48(1).65-74.
[11]	Agdeppa ED,Kepe V,Liu J,et al.In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe2-(1-[6-[(2-[18F]fluoroethyl) (methyl)amino]-2-naphthyl] ethylidene) malononitrile.Neurosci,2003,117(3):723-730.
[12]	Musachio JL,Flesher J,Scheffel UA,et al.Radiosynthesis and mouse brain distribution studies of ¹¹C-CP-126,998:a PET ligand for in vivo study of acetylcholinesterase.Nucl Med Biol,2002,29(5):547-552.
[13]	Zhang MR,Tsuchiyama A,Haradahira T,et al.Synthesis and preliminary evaluation of[¹⁸F] FEtP4A,a promising PET tracer for mapping acetylcholinesterase in vivo.Nucl Med Biol,2002,29(4):463-468.
[14]	Shao X,Lisi JM,Butch ER,et al.N-[¹⁸F] fluoroethylpiperidinyl,N-[¹⁸F] fluoroethylpiperidinemethyl and N-[¹⁸F] fluoroethylpyrrolidinyl esters as radiotracers for acetylcholinesterase.Nucl Med Biol,2003,30(5):491-500.
[15]	Skaddan MB,Sherman PS,Kilbourn,MR,et al.The role of species-dependent metabolism in the regional brain retention of ¹⁸F-labeled muscarinic acetylcholine receptor ligands.Nucl Med Biol,2001,28(7):753-759.
[16]	Cohen VI,Jin BJ,McRee RC,et al.In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiasepinones and pyridobenzodiazepinones.Brain Res,2000,861(2):305-315.
[17]	Piggott M,Owens J,O'Brien J,et al.Comparative distribution of binding of the muscarinic receptor ligands pirenzepine,AF-DX 384,(R,R)-I-QNB and (R,S)-I-QNB to human brain.J Chem Neuroanat,2002,24(3):211-223.
[18]	Koren AO,Horti AG,Mukhin AG,et al.2-,5-,and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines:synthesis,affinity for nicotinic acetylcholinereceptors,and molecular modeling.J Med Chem,1998,41(19):3690-3698.
[19]	Horti AG,Chefer SL,Mukhin AG,et al.6-[¹⁸F] fluoro-A-85380,a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors.Life Sci,2000,67(4):463-469.
[20]	Roger G,Lagnel B,Rouden J,et al.Synthesis of a[2-pyridinyl-¹⁸F]-labelled fluoro derivative of (-)-cytisine as a candidate radioligand for brain nicotinic alpha4beta2 receptor imaging with PET.Bioorg Med Chem,2003,11(24):5333-5343.

[1]	郭喆 , 张锦明 . 阿尔茨海默病的放射性分子显像探针研究进展. 国际放射医学核医学杂志, 2006, 30(4): 199-202.
[2]	宗佳滨 , 兰晓莉 , 张永学 . 阿尔茨海默病分子影像探针的研究进展. 国际放射医学核医学杂志, 2022, 46(1): 35-41. doi: 10.3760/cma.j.cn121381-202101045-00129
[3]	孔艳艳 , 管一晖 , 吴平 . PET分子探针在阿尔茨海默病早期诊断中的研究进展. 国际放射医学核医学杂志, 2012, 36(5): 257-263. doi: 10.3760/cma.j.issn.1673-4114.2012.05.001
[4]	贾建华 , 段玉清 , 侯文彬 , 李祎亮 . 靶向Tau蛋白PET分子探针的研究进展. 国际放射医学核医学杂志, 2020, 44(5): 317-322. doi: 10.3760/cma.j.cn121381-201910028-00031
[5]	王颖 , 蔡莉 , 李彦生 , 高硕 . ¹¹C-PIB PET在不同时期阿尔茨海默病中的研究进展. 国际放射医学核医学杂志, 2013, 37(6): 378-380,384. doi: 10.3760/cma.j.issn.1673-4114.2013.06.013
[6]	蔡莉 , 王颖 , 杨海磊 , 李彦生 . ¹⁸F-AV1451 PET在阿尔茨海默病中的临床研究进展. 国际放射医学核医学杂志, 2020, 44(8): 507-514. doi: 10.3760/cma.j.cn121381-201905004-00056
[7]	肖晴 , 潘芯 , 李崇佼 , 蒋亚群 , 王怡春 , 文兵 , 雷萍 , 何勇 . 转铁蛋白受体靶向分子探针⁹⁹Tc^m-T7的放射性标记及肿瘤显像研究. 国际放射医学核医学杂志, 2022, 46(4): 223-229. doi: 10.3760/cma.j.cn121381-202110017-00167
[8]	钟燕 , 金晨涛 , 张明荣 , 张宏 . PET分子影像在阿尔茨海默病神经炎症中的研究进展. 国际放射医学核医学杂志, 2019, 43(6): 503-509. doi: 10.3760/cma.j.issn.1673-4114.2019.06.003
[9]	张冰 , 徐俊 , 徐运 , 朱斌 . fMRI在阿尔茨海默病、额颞叶痴呆及路易体痴呆中的研究进展. 国际放射医学核医学杂志, 2010, 34(5): 303-307. doi: 10.3760/cma.j.issn.1673-4114.2010.05.015
[10]	韩彦江 , 王猛 , 智生芳 , 徐万帮 . 人血清白蛋白结合型分子探针在核医学诊疗中的研究进展. 国际放射医学核医学杂志, 2023, 47(8): 496-502. doi: 10.3760/cma.j.cn121381-202204020-00330